Manufacturing Challenges & Considerations for Allogeneic Cell Therapy
The allogeneic cell therapy space has many development and manufacturing bottlenecks which are further compounded by the diversity of cell types, delivery systems and gene editing technologies that are now being pursued in the clinic.
To better elucidate these challenges Hanson Wade Intelligence, our Market Research division, spoke to 15 key opinion leaders within the allogeneic cell therapy space. We summarised their views alongside quantitative insights from our Beacon Adoptive Cell database in this opinion review.
This report aims to provide cell therapy developers with valuable insights on the main allogeneic manufacturing challenges and considerations for optimisation of key stages of development.
Autologous vs. Allogeneic CAR-T Therapies
Scale up of manufacturing for allogeneic cells is similar to the techniques used to make protein drugs and other large scale cell derived materials while autologous cells require scale out, the production of many individual products at the same time. Cell & Gene have curated an insightful editorial that concentrates on the advancements of both allogeneic and autologous therapies and how to manufacture them at scale
Allogeneic Cell Therapies: Christmas Reading List
It’s been a whirlwind year for the allogeneic community, comprising of a wealth of advances resulting in the first commercial approval. As we look forward to the 2nd Allogeneic Cell Therapies Summit Europe around the corner, we wanted to gift you these industry highlights from the year.